Together, these data indicate the importance of BRAF V600E mutations [180,181] as well as suggest that IL-1 could serve as a therapeutic target for LCH treatment, especially for prolonged inflammatory process supplied from circulating mutated monocytes in LCH-RO (+) [182]. The gene discussed is BRAF; the disease is Langerhans cell histiocytosis.